Stanford University
Showing 13,721-13,730 of 36,302 Results
-
Yusuke Iguchi
Sr Res Scientist-Physical
Current Research and Scholarly InterestsHis research specialties are in experimental condensed matter physics, magnetic excitations in microwave region, magnetic scanning probe microscopy, multiferroics, and unconventional superconductors. Currently his interest is in the unconventional superconductors such as heavy fermion and iron based ones.
-
Matthias Ihme
Professor of Mechanical Engineering, of Photon Science and, by courtesy, of Energy Science and Engineering
BioLarge-eddy simulation and modeling of turbulent reacting flows, non-premixed flame, aeroacoustics and combustion generated noise, turbulence and fluid dynamics, numerical methods and high-order schemes.
-
Debra M. Ikeda, M.D.
Professor of Radiology (Breast Imaging), Emerita
Current Research and Scholarly InterestsMy research interests are mammography positioning, tomosynthesis (DBT) cancer detection and diagnosis, MRI, DWI, MRI-guided breast biopsy, breast cancer recurrence, tattoo/ fiducial/wire localization of axillary lymph nodes, breast cancer and FDG PET-CT imaging, artifical intelligence/deep learning, breast density, density notification legislation, abscess drainages, mammography positioning
-
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
